CVM vs. GNFT, PSTX, ADAP, IPSC, IPHA, MGX, CADL, IVVD, GLUE, and SCLX
Should you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Genfit (GNFT), Poseida Therapeutics (PSTX), Adaptimmune Therapeutics (ADAP), Century Therapeutics (IPSC), Innate Pharma (IPHA), Metagenomi (MGX), Candel Therapeutics (CADL), Invivyd (IVVD), Monte Rosa Therapeutics (GLUE), and Scilex (SCLX). These companies are all part of the "biological products, except diagnostic" industry.
Genfit (NASDAQ:GNFT) and CEL-SCI (NYSE:CVM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, institutional ownership, media sentiment, valuation and risk.
Genfit received 65 more outperform votes than CEL-SCI when rated by MarketBeat users. Likewise, 68.42% of users gave Genfit an outperform vote while only 0.00% of users gave CEL-SCI an outperform vote.
Genfit has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.
Genfit currently has a consensus target price of $11.00, indicating a potential upside of 102.58%. Given CEL-SCI's higher probable upside, research analysts plainly believe Genfit is more favorable than CEL-SCI.
2.2% of Genfit shares are owned by institutional investors. Comparatively, 12.1% of CEL-SCI shares are owned by institutional investors. 4.2% of Genfit shares are owned by insiders. Comparatively, 16.2% of CEL-SCI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Genfit had 1 more articles in the media than CEL-SCI. MarketBeat recorded 2 mentions for Genfit and 1 mentions for CEL-SCI. CEL-SCI's average media sentiment score of 0.30 beat Genfit's score of 0.00 indicating that Genfit is being referred to more favorably in the media.
Genfit has higher revenue and earnings than CEL-SCI.
CEL-SCI's return on equity of 0.00% beat Genfit's return on equity.
Summary
Genfit beats CEL-SCI on 11 of the 13 factors compared between the two stocks.
Get CEL-SCI News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
